会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NOVEL PYRROLE DERIVATIVES WITH ANGIOTENSIN II ANTAGONIST ACTIVITY
    • 具有血管紧张素II拮抗剂活性的新型吡咯烷酮衍生物
    • WO2005105789A2
    • 2005-11-10
    • PCT/EP2005/051911
    • 2005-04-27
    • ROTTAPHARM S.p.A.MAKOVEC, FrancescoARTUSI, RobertoGIORDANI, AntonioZANZOLA, SimonaROVATI, Lucio Claudio
    • MAKOVEC, FrancescoARTUSI, RobertoGIORDANI, AntonioZANZOLA, SimonaROVATI, Lucio Claudio
    • C07D403/10
    • C07D403/10
    • Compounds which may be represented by the general formula (I) shown below and in which: R 1 is a group independently selected from among: CHO, -COOH, -CH 2 OH R 2 is hydrogen or a linear or branched C 1 -C 6 alkyl group R 3 is hydrogen or a halogen group selected from among Cl and Br R 4 is a linear or branched C 3 -C 5 alkyl group and the pharmaceutically acceptable salts thereof such as the sodium or potassium salt. The compounds exhibit potent and selective All antagonist activity and are useful for the treatment of any disorders in which elevated synthesis of All or overexpression of the AT 1 receptor may play a primary pathological role, as in the case of arterial hypertension, congestive cardiac insufficiency, platelet aggregation and disorders associated therewith such as for example myocardial and cerebral infarction, renal ischaemia, venous and arterial thrombosis, peripheral vasculopathy, pulmonary hypertension, diabetes mellitus, diabetic neuropathy, glaucoma and diabetic retinopathy.
    • 可以由下述通式(I)表示的化合物,其中:R 1是独立地选自:CHO,-COOH,-CH 2 OH的基团R 2是氢或直链或支链C 1 -C 6烷基R 3是氢 或选自Cl和Br R4中的卤素基团是直链或支链C 3 -C 5烷基及其药学上可接受的盐,例如钠盐或钾盐。 该化合物显示出有效和选择性的所有拮抗剂活性,并且可用于治疗其中AT1受体的全部或过度表达的合成升高可能起主要病理作用的任何障碍,如在动脉高血压,充血性心功能不全,血小板 与其相关的聚集和紊乱,例如心肌和脑梗死,肾缺血,静脉和动脉血栓形成,外周血管病变,肺动脉高压,糖尿病,糖尿病性神经病,青光眼和糖尿病性视网膜病变。
    • 2. 发明申请
    • 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS
    • 4,4-二氟 - 哌啶化合物
    • WO2013127913A1
    • 2013-09-06
    • PCT/EP2013/054017
    • 2013-02-28
    • ROTTAPHARM S.P.A.
    • STASI, Luigi PieroROVATI, LucioARTUSI, RobertoBOVINO, ClaraCOLACE, FabrizioMANDELLI, Stefano
    • C07D401/12C07D401/14C07D417/14A61K31/4523A61P25/00
    • C07D401/14C07D401/12C07D417/14
    • The invention, in a first aspect relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a 6-membered aromatic ring, or a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O and N, or a 6-membered benzocondensed heteroaromatic ring containing N as heteroatom, optionally each of said rings being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl, cyano, trifluoromethyl, dimethylamino, or phenyl which optionally is substituted with one or more halogen atoms, or a 5- or 6-membered heterocycle containing from one to three nitrogen atoms; X is O or N; P is pyridyl, pyrimidyl, pyrazyl, or pyridazyl, each being optionally substituted with one or more substituents selected from the group consisting of (C1-C3)alkyl, halogen, trifluoromethyl, and cyano, and use thereof as pharmaceuticals.
    • 本发明在第一方面涉及式(I)化合物或其药学上可接受的盐,其中R是6元芳族环,或含有1至3个选自S的杂原子的5或6元杂芳族环 ,O和N,或含有N作为杂原子的6元苯并稠杂杂芳环,任选地,所述环中的每一个被一个或两个选自(C 1 -C 3)烷基,(C 3 -C 5)环烷氧基, (C 1 -C 3)烷基羰基,氰基,三氟甲基,二甲基氨基或任选被一个或多个卤素原子取代的苯基,或含有1至3个氮原子的5或6元杂环; X是O或N; P是吡啶基,嘧啶基,吡嗪基或哒嗪基,各自任选被一个或多个选自(C 1 -C 3)烷基,卤素,三氟甲基和氰基的取代基取代,并且作为药物使用。